Treatment of SSc fibroblasts with the LATS inhibitor TRULI, which enhances YAP nuclear localization and transcriptional activity, promoted myofibroblast development and increased collagen production, whereas the inverse was observed with TEAD inhibition by verteporfin. This evidence concerns the gene YAP1 and systemic sclerosis.